AXSM — Axsome Therapeutics Share News
0.000.00%
Last trade - 00:00- $7.51bn
- $7.40bn
- $638.50m
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing
U.S. STOCKS ON THE MOVE-Cal-Maine, Rivian, Alkermes
U.S. STOCKS ON THE MOVE-Seagate, nCino, Zymeworks
Axsome rises as it buys rights to experimental schizophrenia drug
Brief: Axsome Therapeutics Initiates Clarity Phase 3 Trial Of Solriamfetol In Adults With Major Depressive Disorder
U.S. RESEARCH ROUNDUP-Dollar General, Keysight Technologies, Teledyne Technologies
Axsome Therapeutics Q4 revenue rises 65% driven by AUVELITY
Brief: Axsome Therapeutics Settles Sunosi® (Solriamfetol) Patent Litigation With Alkem Laboratories Ltd.
U.S. RESEARCH ROUNDUP-Adobe, Exxon Mobil, Stellar Bancorp
U.S. RESEARCH ROUNDUP- Boeing, Carvana, UnitedHealth
U.S. RESEARCH ROUNDUP-Cencora, Kennametal, Regeneron Pharmaceuticals
U.S. RESEARCH ROUNDUP-Axsome Therapeutics, Block, Terawulf
Axsome up after FDA grants priority review for Alzheimer's agitation drug
Brief: Axsome Therapeutics Acquires AZD7325, A Selective GABA-A Modulator For Treatment Of Epilepsy
U.S. RESEARCH ROUNDUP-Affiliated Managers Group, Argenx SE, Cardinal Health Inc
Axsome Therapeutics Q3 net product revenue jumps 63%
U.S. RESEARCH ROUNDUP-Carvana, Marvell Technology, Wayfair
U.S. RESEARCH ROUNDUP- Axon Enterprise, Berkshire Hathaway, Idexx Laboratories
U.S. STOCKS ON THE MOVE-Tyson Foods, BioNTech, gold miners